tipifarnib has been researched along with Carcinoma, Non-Small Cell Lung in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Moulec, S; Loriot, Y; Soria, JC | 1 |
| Li, M; Liu, A; Liu, B; Luo, X; Yu, H; Zheng, H | 1 |
| Busceti, MT; Caraglia, M; Falcone, D; Fratto, D; Gallelli, L; Maselli, R; Pelaia, G; Renda, T; Savino, R; Terracciano, R; Vatrella, A | 1 |
| Adjei, AA; Bruzek, L; Erlichman, C; Geyer, S; Hanson, LJ; Hillman, S; Kaufmann, SH; Marks, RS; Mauer, A; Vokes, EE; Wright, JJ | 1 |
| Khuri, FR | 1 |
| Heymach, JV; Johnson, BE | 1 |
2 review(s) available for tipifarnib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
Farnesyl transferase inhibitors for patients with lung cancer.
Topics: Alkyl and Aryl Transferases; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Farnesyltranstransferase; Humans; Imidazoles; Lung Neoplasms; Quinolones; Signal Transduction; Treatment Outcome | 2004 |
1 trial(s) available for tipifarnib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Anemia; Carcinoma, Non-Small-Cell Lung; Disease Progression; Farnesyltranstransferase; Female; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Neutropenia; Quinolones; Survival | 2003 |
3 other study(ies) available for tipifarnib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Monomeric GTP-Binding Proteins; Multiprotein Complexes; Mutation; Neuropeptides; Phosphorylation; Piperidines; Prenylation; Proteins; Pyridines; Quinolones; Ras Homolog Enriched in Brain Protein; Ribosomal Protein S6; RNA Interference; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2010 |
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Quinolones; Simvastatin | 2012 |